This study explores how the menin inhibitor revumenib induces significant immunophenotypic shifts in AML patients. Results show that over 50% of patients undergo lineage changes, and achieving MRD negativity remains the strongest predictor of long-term survival, necessitating new approaches to flow cytometry monitoring.